Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Paiva, B. (Bruno) | - |
dc.creator | Puig, N. (Noemí) | - |
dc.creator | Cedena, M.T. (María Teresa) | - |
dc.creator | Jong, B.G. (Britt G.) de | - |
dc.creator | Ruiz-Paz, Y, (Yanira) | - |
dc.creator | Rapado, I. (Inmaculada) | - |
dc.creator | Martínez-López, J. (Joaquín) | - |
dc.creator | Cordón, L. (Lourdes) | - |
dc.creator | Alignani, D. (Diego) | - |
dc.creator | Delgado, J.A. (Jose Antonio) | - |
dc.creator | Van Zelm, M.C. (Menno C.) | - |
dc.creator | Dongen, J.J.M. (Jacques J. M.) van | - |
dc.creator | Pascual, M. (Marien) | - |
dc.creator | Agirre-Ena, X. (Xabier) | - |
dc.creator | Prosper-Cardoso, F. (Felipe) | - |
dc.creator | Martin-Subero, J.I. (Jose Ignacio) | - |
dc.creator | Vidriales, M.B. (María Belén) | - |
dc.creator | Gutierrez, N.C. (Norma C.) | - |
dc.creator | Hernandez, M.T. (Miguel Teodoro) | - |
dc.creator | Oriol, A. (Albert) | - |
dc.creator | Echeveste, M.A. (Maria Asuncion) | - |
dc.creator | Gonzalez, Y. (Yolanda) | - |
dc.creator | Johnson, S.K. (Sarah K.) | - |
dc.creator | Epstein, J. (Joshua) | - |
dc.creator | Barlogie, B. (Bart) | - |
dc.creator | Morgan, G.J. (Gareth J.) | - |
dc.creator | Orfao, A. (Alberto) | - |
dc.creator | Bladé, J. (Joan) | - |
dc.creator | Mateos, M.V. (María Victoria) | - |
dc.creator | Lahuerta, J.J. (Juan José) | - |
dc.creator | San-Miguel, J.F. (Jesús F.) | - |
dc.date.accessioned | 2018-05-11T14:52:56Z | - |
dc.date.available | 2018-05-11T14:52:56Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Paiva, B. (Bruno); Puig, N. (Noemí); Cedena, M.T. (María Teresa); et al. "Differentiation stage of myeloma plasma cells: biological and clinical significance". Leukemia. 31 (2), 2017, 382 - 392 | es |
dc.identifier.issn | 0887-6924 | - |
dc.identifier.uri | https://hdl.handle.net/10171/52273 | - |
dc.description.abstract | The notion that plasma cells (PCs) are terminally-differentiated has prevented intensive research in multiple myeloma (MM) about their phenotypic plasticity and differentiation. Here, we demonstrated in healthy individuals (n=20) that the CD19-CD81 expression axis identifies three bone marrow (BM)PC subsets with distinct age-prevalence, proliferation, replication-history, immunoglobulin-production, and phenotype, consistent with progressively increased differentiation from CD19+CD81+ into CD19-CD81+ and CD19-CD81- BMPCs. Afterwards, we demonstrated in 225 newly-diagnosed MM patients that, comparing to normal BMPC counterparts, 59% had fully-differentiated (CD19-CD81-) clones, 38% intermediate-differentiated (CD19-CD81+), and 3% less-differentiated (CD19+CD81+) clones. The latter patients had dismal outcome, and PC differentiation emerged as an independent prognostic marker for progression-free (HR:1.7;P=.005) and overall survival (HR:2.1;P=.006). Longitudinal comparison of diagnostic vs. minimal-residual-disease samples (n=40) unraveled that in 20% of patients, less-differentiated PCs subclones become enriched after therapy-induced pressure. We also revealed that CD81 expression is epigenetically regulated, that less-differentiated clonal PCs retain high expression of genes related to preceding B-cell stages (e.g.:PAX5), and show distinct mutation profile vs. fully-differentiated PC clones within individual patients. Together, we shed new light into PC plasticity and demonstrated that MM patients harboring less-differentiated PCs have dismal survival, which might be related to higher chemoresistant potential plus different molecular and genomic profiles. | es_ES |
dc.description.sponsorship | This study was supported by the Cooperative Research Thematic Network grants RD12/0036/0048, RD12/0036/0058, RD12/0036/0046, RD12/0036/0068, RD12/0036/0069, and RD12/0036/0061 of the Red de Cancer (Cancer Network of Excellence); Instituto de Salud Carlos III, Spain, Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09-/01897/01370; PI13/01469, PI14/01867, G03/136; Sara Borrell: CD13/00340 and CD12/00540); Fundació La Marató de TV3 (20132130-31-32) and Asociación Española Contra el Cáncer (GCB120981SAN). The study was also supported internationally by the International Myeloma Foundation (IMF) Junior Grant, the Black Swan Research Initiative of the IMF, the Multiple Myeloma Research Foundation research fellow award, the Qatar National Research Fund (QNRF) Award No. 7-916-3-237, Marie Curie (LincMHeM-330598), the AACR-Millennium Fellowship in Multiple Myeloma Research (15-40-38-PAIV), Leukemia Research Foundation and the European Research Council (ERC) 2015 Starting Grant. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Nature Publishing Group | es_ES |
dc.relation | info:eu-report/grantAgreement/EC/ERC/680200-MYELOMANEXT | - |
dc.relation | info:eu-repo/grantAgreement/EC/FP7/330598/EU | - |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Materias Investigacion::Ciencias de la Salud::Hematología | es_ES |
dc.subject | Multiple myeloma | es_ES |
dc.title | Differentiation stage of myeloma plasma cells: biological and clinical significance | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://www.ncbi.nlm.nih.gov/pubmed/27479184 | es_ES |
dc.identifier.doi | 10.1038/leu.2016.211 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.